TME Pharma N.V.
ALTME | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NL0015000YE1 (+1 more)
- LEI:
- 724500EPNADXWZ58U595
- Country:
- Germany
- Address:
- Max-Dohrn-Strasse 8-10, 10589 Berlijn
- Website:
- https://www.tmepharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
TME Pharma N.V. is a clinical-stage biotechnology company developing novel therapies for aggressive cancers by targeting the tumor microenvironment (TME). The company's core approach involves neutralizing chemokines within the TME to break down tumor protection barriers and block tumor repair mechanisms. This strategy is designed to enhance the efficacy of complementary treatments, such as radiotherapy and immunotherapy. TME Pharma's lead clinical program, NOX-A12, is in development for difficult-to-treat cancers like glioblastoma and pancreatic cancer. In addition to its primary oncology focus, the company is advancing its NOX-E36 program for ophthalmology applications. TME Pharma was formerly known as NOXXON Pharma.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for TME Pharma N.V..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-18 08:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 255.7 KB | |
| 2025-06-18 08:00 |
M&A Activity
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | |
| 2025-05-27 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 386.1 KB | |
| 2025-05-27 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 388.7 KB | |
| 2025-05-26 08:00 |
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
|
French | 261.4 KB | |
| 2025-05-26 08:00 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 222.6 KB | |
| 2025-05-21 08:00 |
Capital/Financing Update
Informations privilégiées / Autres communiqués
|
French | 329.1 KB | |
| 2025-05-21 08:00 |
Capital/Financing Update
Inside Information / Other news releases
|
English | 286.1 KB | |
| 2025-05-05 18:00 |
Director's Dealing
Inside Information / Other news releases
|
English | 243.3 KB | |
| 2025-05-05 18:00 |
Director's Dealing
Informations privilégiées / Autres communiqués
|
French | 255.1 KB | |
| 2025-05-05 08:00 |
Board/Management Information
Inside Information / Other news releases
|
English | 281.1 KB | |
| 2025-05-05 08:00 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 287.8 KB | |
| 2025-04-25 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 351.1 KB | |
| 2025-04-25 18:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 275.9 KB | |
| 2025-04-10 19:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 224.0 KB |
Automate Your Workflow. Get a real-time feed of all TME Pharma N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for TME Pharma N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
